SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis

Farnesoid X receptor (FXR) is a promising target for nonalcoholic steatohepatitis (NASH) and fibrosis. Although various FXR agonists have shown anti-fibrotic effects in diverse preclinical animal models, the response rate and efficacies in clinical trials were not optimum. Here we report that prophy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Zhou, Jiyu, Cui, Shuang, He, Qingxian, Guo, Yitong, Pan, Xiaojie, Zhang, Pengfei, Huang, Ningning, Ge, Chaoliang, Wang, Guangji, Gonzalez, Frank J., Wang, Hong, Hao, Haiping
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6957516/
https://ncbi.nlm.nih.gov/pubmed/31932588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-14138-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars